Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Isoniazid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.95 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.95 |
| ▸ | MPO | P05164 | 2/20 | 0.95 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.95 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.95 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.95 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.95 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.56 |
| ▸ | KDM5A | P29375 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isoniazid SCHEMBL2390873 | 0.98 | KDM4E (1.00) | KDM4ECYP3A4MPOCYP1A2CYP2D6 | |
| Isoniazid SCHEMBL12264078 | 0.98 | KDM4E (1.00) | KDM4ECYP3A4MPOCYP1A2CYP2D6 | |
| Isoniazid SCHEMBL2072618 | 0.98 | KDM4E (1.00) | KDM4ECYP3A4MPOCYP1A2CYP2D6 | |
| Isoniazid SCHEMBL228 | 0.98 | KDM4E (1.00) | KDM4ECYP3A4MPOCYP1A2CYP2D6 | |
| Isoniazid SCHEMBL16642161 | 0.98 | KDM4E (1.00) | KDM4ECYP3A4MPOCYP1A2CYP2D6 | |
| Isoniazid SCHEMBL12264083 | 0.98 | KDM4E (1.00) | KDM4ECYP3A4MPOCYP1A2CYP2D6 | |
| Isoniazid SCHEMBL16642160 | 0.98 | KDM4E (1.00) | KDM4ECYP3A4MPOCYP1A2CYP2D6 | |
| Isoniazid SCHEMBL12264081 | 0.98 | KDM4E (1.00) | KDM4ECYP3A4MPOCYP1A2CYP2D6 | |
| Isoniazid SCHEMBL7502798 | 0.95 | KDM4E (0.95) | KDM4ECYP3A4MPOCYP1A2CYP2D6 | |
| Isoniazid SCHEMBL20958129 | 0.95 | KDM4E (0.95) | KDM4ECYP3A4MPOCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 2015-08-13 | — | — | US | disclosed |
| US-8987304-B2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| US-20090275528-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-11-05 | — | — | US | disclosed |
| CN-1157190-C | Application of sodium deoxy taurocholate as synergist for antituber culosis antibiotic | 黄林君 | 2004-07-14 | — | — | CN | disclosed |
| EP-0665009-B1 | CRYSTALLINE CONDITION DISLOCATING METHOD | NIPPON SHINYAKU CO LTD (JP) | 2000-02-16 | — | — | EP | disclosed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | disclosed |
| EP-0665009-A1 | CRYSTALLINE CONDITION DISLOCATING METHOD | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1995-08-02 | — | — | EP | disclosed |
| US-4013758-A | PROCESS FOR PREPARING HYDRAZINES | OSBORG HANS | 1977-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | KDM4E 2723/4885CYP3A4 72/4885MPO 919/4885 |
| US-20090275528-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | KDM4E 2723/4885CYP3A4 72/4885MPO 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.